Department of Immunology and Infectious Disease, John Curtin School of Medical Research, the Australian National University, Canberra, ACT 2601, Australia.
Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Cell Host Microbe. 2020 Oct 7;28(4):572-585.e7. doi: 10.1016/j.chom.2020.07.001. Epub 2020 Jul 21.
Generating sufficient antibody to block infection is a key challenge for vaccines against malaria. Here, we show that antibody titers to a key target, the repeat region of the Plasmodium falciparum circumsporozoite protein (PfCSP), plateaued after two immunizations in a clinical trial of the radiation-attenuated sporozoite vaccine. To understand the mechanisms limiting vaccine responsiveness, we developed immunoglobulin (Ig)-knockin mice with elevated numbers of PfCSP-binding B cells. We determined that recall responses were inhibited by antibody feedback, potentially via epitope masking of the immunodominant PfCSP repeat region. Importantly, the amount of antibody that prevents boosting is below the amount of antibody required for protection. Finally, while antibody feedback limited responses to the PfCSP repeat region in vaccinated volunteers, potentially protective subdominant responses to PfCSP C-terminal regions expanded with subsequent boosts. These data suggest that antibody feedback drives the diversification of immune responses and that vaccination for malaria will require targeting multiple antigens.
产生足够的抗体来阻断感染是疟疾疫苗的一个关键挑战。在这里,我们表明,在辐射减毒孢子疫苗的临床试验中,两次免疫后,针对关键靶标——疟原虫环子孢子蛋白(PfCSP)重复区的抗体滴度达到平台期。为了了解限制疫苗反应性的机制,我们开发了免疫球蛋白(Ig)基因敲入小鼠,这些小鼠具有数量增加的 PfCSP 结合 B 细胞。我们确定,抗体反馈抑制了回忆反应,可能是通过免疫显性 PfCSP 重复区的表位掩蔽。重要的是,阻止增强的抗体量低于保护所需的抗体量。最后,虽然抗体反馈限制了接种疫苗的志愿者对 PfCSP 重复区的反应,但对 PfCSP C 末端区域的潜在保护性亚显性反应随着随后的增强而扩大。这些数据表明,抗体反馈驱动免疫反应的多样化,而疟疾疫苗接种将需要针对多个抗原。